Professor Dipti Talaulikar

MBBS, PhD, FRACP, FRCPA, Grad Cert HE
Haematology Staff Specialist, Canberra Health Services
Honorary Professor, ANU School of Medicine and Psychology

Dipti is a physician scientist and senior staff specialist in Haematology She obtained her fellowships for RACP and RCPA in 2006-07 and completed her PhD at ANU (2006-2009). She is a Senior Fellow of the Higher Education Academy.

She is the founder leader of the Haematology Translational Research Unit which focuses on blood cancer research, and of the Haematology Research Tissue Bank, a repository of peripheral blood, bone marrow and primary tissue samples from patients with haematological and related disorders.The Haematology Research Tissue Bank has resulted in strong research collaborations within and outside ANU, with 23 publications and 500+ citations (as of Oct 2022).

Her innovative and inclusive teaching programs have won her 4 university teaching and education awards.

Dipti has used her clinical experience and knowledge of 2 countries and healthcare systems to develop and lead a program called "The Link" which focusses on global healthcare equity and support and promotion of diverse healthcare professionals.

As an advocate for gender equity and diversity, she was a finalist for the ACT Woman of the Year award this year and has been inducted on the honour roll.

Awards include: 1. ACT Woman of the Year finalist and Honour Roll Inductee (2023), 2. College of Health and Medicine innovation award for The Link: ANU COVID-19 Peer Support program (2021) 3. Vice Chancellor award for teaching excellence (2020) 4. Vice Chancellor award for excellence in education (2020) 5. Award for Excellence in Medical Education (Innovation), ANU Medical School (2018) 6. Dean's award for contribution to teaching, for developing a bedside teaching program for medical students (2013)

Specialisation

  • Haematology
  • Pathology

Research interests

The Haematology Translational Research Unit is involved with translational research projects in lymphoproliferative disorders including lymphoma and myeloma.

Partciular areas of interest are:

1. Determining the cellular origin of lymphoma using a combination of sophisticated flow cytometry and cell sorting, genotyping and ultra deep sequencing techniques,

2. Etsablishing links between autoimmunity and lymphoma

3. Drug screening and repurposing

3. Bleeding in haematological disorders

Our projects include work on archived human tissue samples stored at the Haematology Research Tissue Bank.

  • Talaulikar, D, Tomowiak, C, Toussaint, E et al. 2023, 'Evaluation and Management of Disease Transformation in Waldenstr�m Macroglobulinemia', Hematology/Oncology Clinics of North America, vol. 37, no. 4, pp. 787-799.
  • Petvises, S, Tran, V, Hey, Y et al. 2022, 'Extramedullary hematopoiesis: mesenchymal stromal cells from spleen provide an in vitro niche for myelopoiesis', In Vitro Cellular and Developmental Biology - Animal, vol. 58, no. 5, pp. 429-439.
  • Brysland, S, Maqbool, M, Talaulikar, D et al. 2022, 'Bleeding Propensity in Waldenstr�m Macroglobulinemia: Potential Causes and Evaluation', Thrombosis and Haemostasis, vol. 122, no. 11, pp. 1843-1857.
  • Talaulikar, D 2021, 'Malignant haematology 2021: impact of recent advances on the diagnostic laboratory', Pathology, vol. 53, no. 3, pp. 297-299.
  • Lim, J, Kuss, B & Talaulikar, D 2021, 'Role of cell-free DNA in haematological malignancies', Pathology, vol. 53, no. 3, pp. 416-426.
  • Harrington, F, Greenslade, M, Talaulikar, D et al. 2021, 'Genomic characterisation of diffuse large B-cell lymphoma', Pathology, vol. 53, no. 3, pp. 367-376.
  • Nath, K, Law, S, Sabdia, M et al. 2021, 'Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma', Blood Advances, vol. 5, no. 12, pp. 2644-2649.
  • Talaulikar, D, Opat, S, Opat, S et al. 2021, 'The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma', Clinical Cancer Research, vol. 27, no. 23, pp. 6323-6332.
  • Creeper, K, Augustson, B, Kusel, K et al. 2021, 'Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia', Internal Medicine Journal, vol. 51, no. 10, pp. 1707-1712.
  • Boyle, S, Tobin, J, Perram, J et al. 2021, 'Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance', HemaSphere, vol. 5, no. 11, pp. 1 - 8.
  • Wilson, C, Lee, W, Cook, M et al. 2021, 'Correlation of haemophagocytosis with clinical criteria of haemophagocytic lymphohistiocytosis and recommendations for bone marrow reporting', Pathology, vol. 54, no. 4, pp. 434-441.
  • Keane, C, Law, S, Gould, C et al. 2020, 'LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma', Blood Advances, vol. 4, no. 7, pp. 1367-1377.
  • Rijal, S, Kok, J, Coombes, C et al. 2020, 'High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(-/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma', BMC Cancer, vol. 20, no. 1, pp. 1-9.
  • Castillo, J, Advani, R, Branagan, A et al. 2020, 'Consensus treatment recommendations from the tenth International Workshop for Waldenstr�m Macroglobulinaemia', The Lancet Haematology, vol. 7, no. 11, pp. e827-e837.
  • Dimopoulos, M, Garcia-Sanz, R, Lee, H et al. 2020, 'Zanubrutinib for the treatment of MYD88 wild-type Waldenstr�m macroglobulinemia: a substudy of the phase 3 ASPEN trial', Blood Advances, vol. 4, no. 23, pp. 6009-6018.
  • Talaulikar, D, Advani, R, Branagan, A et al. 2020, 'Consensus Statement on the Management of Waldenstr�m Macroglobulinemia Patients During the COVID-19 Pandemic', HemaSphere, vol. 4, no. 4, pp. 1-4.
  • Maqbool Gohar.....Dipti Talaulikar 2020, 'A practical guide to laboratory investigations at diagnosis and follow up in Waldenstrom macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases', Pathology, vol. 52, no. 2, pp. 167-178.
  • Wight, J, Yue, M, Keane, C et al. 2019, 'Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance', British Journal of Haematology, vol. 187, no. 2, pp. 174-184.
  • Castillo, J, Itchaki, G, Paludo, J et al. 2019, 'Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study', Blood, vol. 133, no. 4, pp. 299-305.
  • Vari, F, Arpon, D, Keane, C et al. 2018, 'Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL', Blood, vol. 131, no. 16, pp. 1809-1819.
  • Keane, C, Tobin, J, Talaulikar, D et al. 2018, 'A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival', Oncotarget, vol. 9, no. 34, pp. 23620-23627.
  • Talaulikar, D, Lim, J, Wang, J et al 2017, 'Plasma cells arise from differentiation of clonal lymphocytes and secrete IGM in Waldenstrom Macroglobulinemia', 22nd Congress of the European Hematology Association, ed. Jan Cools (Leuven), Ferrata Storti Foundation, Italy, pp. Volume: 102, Supplement 2, pages 569-570.
  • El-Ayoubi, A, Wang, J, Hein, N et al 2017, 'Role of plasma cells in Waldenström macroglobulinaemia', Pathology, vol. 49, no. 4, pp. 337-345pp.
  • Keane, C, Gould, C, Jones, K et al. 2017, 'The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma', Clinical Cancer Research, vol. 23, no. 7, pp. 1820-1828.
  • Talaulikar, D, Tam, C, Joshua, D et al. 2017, 'Treatment of patients with Waldenstr?m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 47, no. 1, pp. 35-49.
  • Talaulikar, D, Tam, C, Joshua, D et al. 2017, 'Treatment of patients with Waldenstr?m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 47, no. 1, pp. 35-49.
  • Lee, O, Horvath, N, Lee, C et al. 2017, 'Bisphosphonate guidelines for treatment and prevention of myeloma bone disease', Internal Medicine Journal, vol. 47, no. 8, pp. 938-951.
  • Andrews, D, Jeelall, Y, Talaulikar, D et al. 2016, 'DeepSNVMiner: A sequence analysis tool to detect emergent, rare mutations in subsets of cell populations', PeerJ, vol. 4, no. 5, pp. -.
  • Petvises, S, Talaulikar, D & O'Neill, H 2016, 'Delineation of a novel dendritic-like subset in human spleen', Cellular and Molecular Immunology, vol. 13, no. 4, pp. 443-450.
  • Le Cao, K, Keane, C, Han, E et al. 2015, 'Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios', Big Data and Healthcare Analytics 2015, BigData-HISA 2015, ed. K. Barbuto, L. Schaper, K. Vespoor, CEUR-WS.ORG, TBC, pp. -.
  • Keane, C, Vari, F, Hertzberg, M et al. 2015, 'Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: A population-based study', The Lancet Haematology, vol. 2, no. 10, pp. E445-E455.
  • Keane, C, Vari, F, Hertzberg, M et al. 2015, 'Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: A population-based study', The Lancet Haematology, vol. 2, no. 10, pp. E445-E455.
  • Quach, H, Joshua, D, Ho, J et al 2015, 'Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 45, no. 1, pp. 94-105.
  • Weber, N, Mollee, P, Augustson, B et al 2015, 'Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 45, no. 4, pp. 371-382.
  • Quach, H, Joshua, D, Ho, J et al 2015, 'Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 45, no. 3, pp. 335-343.
  • Subramaniam, K, Yeung, D, Grimpen, F et al 2014, 'Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?', Internal Medicine Journal, vol. 44, no. 3, pp. 287-290.
  • Eslick, R & Talaulikar, D 2013, 'Multiple myeloma: from diagnosis to treatment', Australian Family Physician, vol. 42, no. 10, pp. 684-688.
  • Phillips, D, Talaulikar, D, Hawkins, C et al 2013, 'Utilisation of sFLC assays - how well do we comply with guidelines?', International Journal of Laboratory Hematology, vol. 35, no. 2, pp. 200-210.
  • Chen, T, McDonald, A, Shadbolt, F et al. 2012, 'Precision of Histological Bone Marrow Staging in Follicular Lymphoma and Diffuse Large B-cell Lymphoma', Clinical and Investigative Medicine, vol. 35, no. 6, pp. E358-E364.
  • McNiven, M & Talaulikar, D 2012, 'Establishment of a conversion factor for the Cepheid GeneXpert BCR-ABL assay', Pathology, vol. 44, no. 1, pp. 55-57.
  • Talaulikar, D, Tridgell, D, Leong, D et al 2010, 'Novel therapeutic option for orbital atypical lymphoid hyperplasia', Clinical and Experimental Ophthalmology, vol. 38, no. 9, pp. 892-894.
  • Talaulikar, D, Shadbolt, F, Dahlstrom, J et al. 2009, 'Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI)', Journal of Hematology and Oncology, vol. 2, no. 49, p. 36.
  • Talaulikar, D & Dahlstrom, J 2009, 'Staging bone marrow in diffuse large B-cell lymphoma: the role of ancillary investigations', Pathology, vol. 41, no. 3, pp. 214-222.
  • Talaulikar, D, Dahlstrom, J, Shadbolt, F et al. 2008, 'Role of Immunohistochemistry in staging diffuse large B-cell Lymphoma (DLBCL)', Journal of Histochemistry and Cytochemistry, vol. 56, no. 10, pp. 893-900.
  • Talaulikar, D, Shadbolt, F, McNiven, M et al. 2008, 'DNA amplification from formalin-fixed decalcified paraffin-embedded bone marrow trephine specimens: does the duration of storage matter?', Pathology, vol. 40, no. 7, pp. 702-706.
  • Talaulikar, D, Gray, J, Shadbolt, F et al. 2008, 'A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods', Journal of Clinical Pathology, vol. 61, pp. 119-123.
  • Talaulikar, D, Choudhury, A, Shadbolt, F et al. 2008, 'Lymphocytopenia as a Prognostic Marker for Diffuse Large B Cell Lymphoma', Leukemia & Lymphoma, vol. 49, no. 5, pp. 959-964.
  • Talaulikar, D, Sachse-Akerlind, G & Potter, J 2008, 'Bench work and clinical relevance: a new strategy in pathology education', Pathology, vol. 40, no. 7, pp. 707-710.
  • Talaulikar, D, Shadbolt, F, Bell, J et al. 2008, 'Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) - a new perspective', Histopathology, vol. 52, pp. 340-347.
  • Talaulikar, D, Falk, M, Talaulikar, G et al 2007, 'Immune Thrombocytopenia after Renal Transplantation for IgA Nephropathy', Acta Haematologica, vol. 117, pp. 65-67.
  • Talaulikar, D, Dahlstrom, J, Shadbolt, F et al. 2007, 'Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study', Pathology, vol. 39, no. 6, pp. 580-585.
  • Talaulikar, D, Shadbolt, F, McDonald, A et al. 2006, 'Health-related quality of life in chronic coagulation disorders', Haemophilia, vol. 12, no. 6, pp. 633-642.